Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 99.0% in June
by Mitch Edgeman · The Markets DailyProvectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) was the recipient of a large drop in short interest in June. As of June 30th, there was short interest totaling 7,766 shares, a drop of 99.0% from the June 15th total of 802,784 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 285,814 shares, the days-to-cover ratio is presently 0.0 days.
Provectus Biopharmaceuticals Trading Down 1.7%
PVCT stock traded down $0.00 during trading on Friday, hitting $0.07. The stock had a trading volume of 63,360 shares, compared to its average volume of 159,340. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.10. The company’s 50-day moving average price is $0.07 and its two-hundred day moving average price is $0.06.
About Provectus Biopharmaceuticals
Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.
PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.